Community Pharmacy in Health Care Homes
Health Care Homes are existing general practices or Aboriginal Community Controlled Health Services (ACCHS) which will provide better coordinated and more flexible care for up to 65,000 Australians living with chronic and complex conditions.
Almost 200 medical practices and ACCHS around Australia are now providing Health Care Home services to patients with chronic and complex conditions. The stage one trial of Health Care Homes commenced on 1 October 2017 and will conclude on 30 November 2019.
The Health Care Homes model is designed to help Australians better manage their conditions by giving them access to coordinated, integrated care, tailored to their needs.
Community pharmacies, together with other primary health professionals have a key role to play in the success of Health Care Homes and will be important members of the care team.
As part of this initiative, eligible Health Care Homes’ patients will benefit from patient-centred, coordinated medication management services delivered by their community pharmacy of choice in conjunction with their Health Care Home, including an initial reconciliation of their medications and development of a collaborative Medication Management Plan (MMP).
This will be supported by regular follow-up reviews by the community pharmacy, in consultation with the Health Care Home, to maximise continuity of care and improved medication management.
Community pharmacy and the Health Care Home care team will work together to deliver the MMP, to ensure that the patient’s medication goals are achieved and to support their patients in change management and lifestyle approaches.
Participating pharmacies will receive a bundled payment for providing a range of services over the 18 month trial period, including developing and delivering the MMP, undertaking follow-up reviews with the patient and providing other support services for Tier 2 and Tier 3 patients which may include Dose Administration Aids (DAAS), blood pressure monitoring, blood glucose monitoring etc.
Total per patient capped
bundled payment over 18 month trial period*
*To be paid in instalments following development of the MMP and after each patient follow-up review.